Literature DB >> 27108303

Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.

Jazlyn Read1,2, Judith Symmons3, Jane M Palmer3, Grant W Montgomery3, Nicholas G Martin3, Nicholas K Hayward3.   

Abstract

Familial cancer risk has been proposed as a shared feature of many cancers, and overall susceptibility is influenced by combinations of low to moderate risk polymorphisms, rare high penetrance germline mutations, and modulation of risk by environmental and genetic factors. Clustering of melanoma occurs in approximately 10 % of families, and an over-representation of additional cancers has been noticed in some 'melanoma' families. The degree to which other cancers aggregate in families affected by melanoma has not been well defined. Therefore, this study aimed to assess the risk of cancers other than melanoma in a cohort of 178 'intermediate risk' melanoma families, not selected for specific genetic mutations. Families designated as 'intermediate risk' had two first degree relatives (FDRs) affected by melanoma when ascertained between 1982 and 1990, and were followed up over a 33 year period to assess new occurrences of cancer. We included 414 melanoma cases and 529 FDRs, comprising 25,264 person years of observation. Standardised incidence ratios and their 95 % confidence intervals were calculated for all invasive cancers, comparing observed to expected cases of cancer based on age and sex specific incidence rates for the Queensland population. Statistically significant increases were found for bladder cancer in females (observed, 7; expected, 1.99; SIR, 3.52; 95 % CI 1.41-7.25), lymphoid leukaemia in females (observed, 6; expected, 1.75; SIR, 3.43; 95 % CI 1.26-7.46), and myeloma in female melanoma cases (observed, 4; expected, 0.82; SIR, 4.89; 95 % CI 1.33-12.52). Over-representation of bladder cancer, lymphoid leukaemia, and myeloma in females of the cohort may suggest sex-dependent co-modifiers, and it is possible that specific combinations of polymorphisms predispose to certain cancer types.

Entities:  

Keywords:  Bladder cancer; Familial cancer; Lymphoid leukaemia; Melanoma; Risk

Mesh:

Year:  2016        PMID: 27108303     DOI: 10.1007/s10689-016-9907-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  57 in total

Review 1.  Familial risks and temporal incidence trends of multiple myeloma.

Authors:  Andrea Altieri; Bowang Chen; Justo Lorenzo Bermejo; Felipe Castro; Kari Hemminki
Journal:  Eur J Cancer       Date:  2006-06-06       Impact factor: 9.162

2.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  A cohort study of cancer risk in relation to family histories of cancer in the Utah population database.

Authors:  Richard A Kerber; Elizabeth O'Brien
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

4.  Bladder cancer in cancer patients: population-based estimates from a large Swedish study.

Authors:  J Lorenzo Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

5.  The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures.

Authors:  Amanda J Baxter; Maria Celia Hughes; Marina Kvaskoff; Victor Siskind; Sri Shekar; Joanne F Aitken; Adele C Green; David L Duffy; Nicholas K Hayward; Nicholas G Martin; David C Whiteman
Journal:  Twin Res Hum Genet       Date:  2008-04       Impact factor: 1.587

Review 6.  Chronic lymphocytic leukemia radiogenicity: a systematic review.

Authors:  Sharon R Silver; Shannon L Hiratzka; Mary K Schubauer-Berigan; Robert D Daniels
Journal:  Cancer Causes Control       Date:  2007-08-13       Impact factor: 2.506

7.  The Queensland Familial Melanoma Project: study design and characteristics of participants.

Authors:  J F Aitken; A C Green; R MacLennan; P Youl; N G Martin
Journal:  Melanoma Res       Date:  1996-04       Impact factor: 3.599

8.  Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.

Authors:  Michael L Nickerson; Garrett M Dancik; Kate M Im; Michael G Edwards; Sevilay Turan; Joseph Brown; Christina Ruiz-Rodriguez; Charles Owens; James C Costello; Guangwu Guo; Shirley X Tsang; Yingrui Li; Quan Zhou; Zhiming Cai; Lee E Moore; M Scott Lucia; Michael Dean; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2014-09-15       Impact factor: 12.531

9.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

10.  High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.

Authors:  Hildur Helgadottir; Veronica Höiom; Göran Jönsson; Rainer Tuominen; Christian Ingvar; Ake Borg; Håkan Olsson; Johan Hansson
Journal:  J Med Genet       Date:  2014-06-16       Impact factor: 6.318

View more
  1 in total

1.  Germline variants at SOHLH2 influence multiple myeloma risk.

Authors:  Laura Duran-Lozano; Gudmar Thorleifsson; Aitzkoa Lopez de Lapuente Portilla; Abhishek Niroula; Molly Went; Malte Thodberg; Maroulio Pertesi; Ram Ajore; Caterina Cafaro; Pall I Olason; Lilja Stefansdottir; G Bragi Walters; Gisli H Halldorsson; Ingemar Turesson; Martin F Kaiser; Niels Weinhold; Niels Abildgaard; Niels Frost Andersen; Ulf-Henrik Mellqvist; Anders Waage; Annette Juul-Vangsted; Unnur Thorsteinsdottir; Markus Hansson; Richard Houlston; Thorunn Rafnar; Kari Stefansson; Björn Nilsson
Journal:  Blood Cancer J       Date:  2021-04-19       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.